These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12819059)

  • 1. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
    Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
    Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
    van der Voort ER; van der Ley P; van der Biezen J; George S; Tunnela O; van Dijken H; Kuipers B; Poolman J
    Infect Immun; 1996 Jul; 64(7):2745-51. PubMed ID: 8698504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
    Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
    Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.
    Milagres LG; Gorla MC; Sacchi CT; Rodrigues MM
    Infect Immun; 1998 Oct; 66(10):4755-61. PubMed ID: 9746575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.
    Vermont CL; Van Dijken HH; De Groot R; Van Alphen L; Van Den Dobbelsteen GP
    Vaccine; 2004 Aug; 22(23-24):3008-13. PubMed ID: 15297049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
    Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
    Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
    Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.
    Sanders H; Norheim G; Chan H; Dold C; Vipond C; Derrick JP; Pollard AJ; Maiden MC; Feavers IM
    PLoS One; 2015; 10(10):e0140345. PubMed ID: 26466091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
    Boutriau D; Poolman J; Borrow R; Findlow J; Domingo JD; Puig-Barbera J; Baldó JM; Planelles V; Jubert A; Colomer J; Gil A; Levie K; Kervyn AD; Weynants V; Dominguez F; Barberá R; Sotolongo F
    Clin Vaccine Immunol; 2007 Jan; 14(1):65-73. PubMed ID: 17065257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
    Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
    J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.
    Jordens JZ; Williams JN; Jones GR; Christodoulides M; Heckels JE
    Infect Immun; 2004 Nov; 72(11):6503-10. PubMed ID: 15501781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
    Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
    Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.